Association of γH2AX at diagnosis with chemotherapy outcome in patients with breast cancer

Sherry X. Yang, Eric Polley, Dat Nguyen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

γH2AX plays a role in DNA damage response signaling and facilitates the repair of DNA double strand breaks. However, it remains unknown whether constitutive tumor γH2AX expression is associated with treatment outcome in patients. γH2AX status was detected in primary tumors from 24% of 826 patients with stage I, II and III breast cancer by immunohistochemistry; overall survival was analyzed by Kaplan-Meier method. At median follow-up of 176 months (range 13 -282 months), we found substantial survival heterogeneity in γH2AX-positive patients (P=0.002)among uniform treatment groups including radiation or endocrine therapy alone and no-treatment, as well as chemotherapy alone (being worst), in contrast to γH2AX-negative patients (P=0.2). In the chemotherapy group (n=118), median survival was 63 months (95%confidence interval [CI], 29 - 83) in patients with γH2AX-positive tumors compared with 170 months (95% CI 94 - 235) in those with γH2AX-negative tumors (P=0.0017). γH2AX remained a poor prognosis factor in the group by multivariable analysis (adjusted hazard ratio 2.12, P=0.009).Our data demonstrate that constitutive γH2AX positivity is significantly associated with survival heterogeneity in patients among uniform treatment groups, and its expression at diagnosis independently predicts poor chemotherapy outcome in breast cancer.

Original languageEnglish (US)
Pages (from-to)945-951
Number of pages7
JournalTheranostics
Volume7
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Breast Neoplasms
Drug Therapy
Survival
Neoplasms
Confidence Intervals
Double-Stranded DNA Breaks
Therapeutics
DNA Damage
Immunohistochemistry
Radiation

Keywords

  • Breast cancer
  • Chemotherapy
  • Overall survival
  • Standard therapy
  • γH2AX expression

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Association of γH2AX at diagnosis with chemotherapy outcome in patients with breast cancer. / Yang, Sherry X.; Polley, Eric; Nguyen, Dat.

In: Theranostics, Vol. 7, No. 4, 01.01.2017, p. 945-951.

Research output: Contribution to journalArticle

@article{15e60aa9de5444da8ab7fba469ade222,
title = "Association of γH2AX at diagnosis with chemotherapy outcome in patients with breast cancer",
abstract = "γH2AX plays a role in DNA damage response signaling and facilitates the repair of DNA double strand breaks. However, it remains unknown whether constitutive tumor γH2AX expression is associated with treatment outcome in patients. γH2AX status was detected in primary tumors from 24{\%} of 826 patients with stage I, II and III breast cancer by immunohistochemistry; overall survival was analyzed by Kaplan-Meier method. At median follow-up of 176 months (range 13 -282 months), we found substantial survival heterogeneity in γH2AX-positive patients (P=0.002)among uniform treatment groups including radiation or endocrine therapy alone and no-treatment, as well as chemotherapy alone (being worst), in contrast to γH2AX-negative patients (P=0.2). In the chemotherapy group (n=118), median survival was 63 months (95{\%}confidence interval [CI], 29 - 83) in patients with γH2AX-positive tumors compared with 170 months (95{\%} CI 94 - 235) in those with γH2AX-negative tumors (P=0.0017). γH2AX remained a poor prognosis factor in the group by multivariable analysis (adjusted hazard ratio 2.12, P=0.009).Our data demonstrate that constitutive γH2AX positivity is significantly associated with survival heterogeneity in patients among uniform treatment groups, and its expression at diagnosis independently predicts poor chemotherapy outcome in breast cancer.",
keywords = "Breast cancer, Chemotherapy, Overall survival, Standard therapy, γH2AX expression",
author = "Yang, {Sherry X.} and Eric Polley and Dat Nguyen",
year = "2017",
month = "1",
day = "1",
doi = "10.7150/thno.19102",
language = "English (US)",
volume = "7",
pages = "945--951",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "4",

}

TY - JOUR

T1 - Association of γH2AX at diagnosis with chemotherapy outcome in patients with breast cancer

AU - Yang, Sherry X.

AU - Polley, Eric

AU - Nguyen, Dat

PY - 2017/1/1

Y1 - 2017/1/1

N2 - γH2AX plays a role in DNA damage response signaling and facilitates the repair of DNA double strand breaks. However, it remains unknown whether constitutive tumor γH2AX expression is associated with treatment outcome in patients. γH2AX status was detected in primary tumors from 24% of 826 patients with stage I, II and III breast cancer by immunohistochemistry; overall survival was analyzed by Kaplan-Meier method. At median follow-up of 176 months (range 13 -282 months), we found substantial survival heterogeneity in γH2AX-positive patients (P=0.002)among uniform treatment groups including radiation or endocrine therapy alone and no-treatment, as well as chemotherapy alone (being worst), in contrast to γH2AX-negative patients (P=0.2). In the chemotherapy group (n=118), median survival was 63 months (95%confidence interval [CI], 29 - 83) in patients with γH2AX-positive tumors compared with 170 months (95% CI 94 - 235) in those with γH2AX-negative tumors (P=0.0017). γH2AX remained a poor prognosis factor in the group by multivariable analysis (adjusted hazard ratio 2.12, P=0.009).Our data demonstrate that constitutive γH2AX positivity is significantly associated with survival heterogeneity in patients among uniform treatment groups, and its expression at diagnosis independently predicts poor chemotherapy outcome in breast cancer.

AB - γH2AX plays a role in DNA damage response signaling and facilitates the repair of DNA double strand breaks. However, it remains unknown whether constitutive tumor γH2AX expression is associated with treatment outcome in patients. γH2AX status was detected in primary tumors from 24% of 826 patients with stage I, II and III breast cancer by immunohistochemistry; overall survival was analyzed by Kaplan-Meier method. At median follow-up of 176 months (range 13 -282 months), we found substantial survival heterogeneity in γH2AX-positive patients (P=0.002)among uniform treatment groups including radiation or endocrine therapy alone and no-treatment, as well as chemotherapy alone (being worst), in contrast to γH2AX-negative patients (P=0.2). In the chemotherapy group (n=118), median survival was 63 months (95%confidence interval [CI], 29 - 83) in patients with γH2AX-positive tumors compared with 170 months (95% CI 94 - 235) in those with γH2AX-negative tumors (P=0.0017). γH2AX remained a poor prognosis factor in the group by multivariable analysis (adjusted hazard ratio 2.12, P=0.009).Our data demonstrate that constitutive γH2AX positivity is significantly associated with survival heterogeneity in patients among uniform treatment groups, and its expression at diagnosis independently predicts poor chemotherapy outcome in breast cancer.

KW - Breast cancer

KW - Chemotherapy

KW - Overall survival

KW - Standard therapy

KW - γH2AX expression

UR - http://www.scopus.com/inward/record.url?scp=85014451165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014451165&partnerID=8YFLogxK

U2 - 10.7150/thno.19102

DO - 10.7150/thno.19102

M3 - Article

VL - 7

SP - 945

EP - 951

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 4

ER -